Ross Dolan

Senior Clinical Lecturer

University of Dundee

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ross Dolan is a Senior Clinical Lecturer at the University of Dundee, UK. His research primarily focuses on the interplay between systemic inflammation, body composition, and survival in cancer patients, particularly in colorectal and lung cancers. Recent publications encompass diverse topics such as cancer cachexia, the impact of inflammation on prognosis, and the relationship between body composition measurements and clinical outcomes.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (2)

Donald C. McMillan

University of Glasgow

UNITED KINGDOM

View details

Richard J E Skipworth

University of Edinburgh

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ross Dolan

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The relationship between tumour necrosis, systemic inflammation, body composition and survival in patients with colon cancer

RE: Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)

The Relationship between Liver Volume, Clinicopathological Characteristics and Survival in Patients Undergoing Resection with Curative Intent for Non-Metastatic Colonic Cancer

Lactate dehydrogenase: relationship with the diagnostic GLIM criterion for cachexia in patients with advanced cancer

The Impact of Acute Systemic Inflammation Secondary to Oesophagectomy and Anastomotic Leak on Computed Tomography Body Composition Analyses

The relationship between clinicopathological variables, systemic inflammation, and CT‐derived body composition with survival in patients with advanced non‐small cell lung cancer receiving nivolumab as a second‐line treatment

Are CT-Derived Muscle Measurements Prognostic, Independ-ent of Systemic Inflammation, in Good Performance Status Pa-tients with Advanced Cancer?

Inflammation and performance status: the cornerstones of prognosis in advanced cancer

Cancer cachexia: a nutritional or a systemic inflammatory syndrome?

Relation Between Body Composition, Systemic Inflammatory Response, and Clinical Outcomes in Patients Admitted to an Urban Teaching Hospital with COVID-19

Collaborators (2)

Donald C. McMillan

Richard J E Skipworth

Make your next move.